Sugi Predict

Sugi Predict / Compounds / SCHEMBL13496830

SCHEMBL13496830

SCHEMBL13496830

Cc1[nH]c2c(F)cc(F)cc2c1CCN

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ HTR1D P28221 3/20 0.46
▸ HTR6 P50406 2/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ HTR7 P34969 1/20 0.46
▸ HTR3A P46098 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ KRAS P01116 1/20 0.40
▸ RAD52 P43351 1/20 0.39
▸ BLM P54132 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ GPR84 Q9NQS5 1/20 0.39
▸ HTR2A P28223 3/20 0.38
▸ TRPM8 Q7Z2W7 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30579451 1.00 SMN1; SMN2 (0.49) SMN1; SMN2HTR1DHTR6TDP1CYP1A2
Hydrochloric Acid SCHEMBL29359092 0.98 SMN1; SMN2 (0.51) SMN1; SMN2HTR1DHTR6TDP1CYP1A2
SCHEMBL3230557 0.85 KRAS (0.47) SMN1; SMN2HTR1DHTR6TDP1CYP1A2
SCHEMBL13496832 0.83 SMN1; SMN2 (0.47) SMN1; SMN2HTR1DHTR6TDP1CYP1A2
SCHEMBL3234383 0.83 SMN1; SMN2 (0.47) SMN1; SMN2HTR1DHTR6TDP1CYP1A2
SCHEMBL3228500 0.83 KRAS (0.51) SMN1; SMN2HTR1DHTR6TDP1CYP1A2
SCHEMBL22454062 0.82 GPR84 (0.44) SMN1; SMN2HSD17B10GPR84KDM4EPTGS1
SCHEMBL3231396 0.81 SMN1; SMN2 (0.55) SMN1; SMN2HTR1DHTR6TDP1CYP1A2
SCHEMBL3232335 0.81 HTR1D (0.61) SMN1; SMN2HTR1DHTR6TDP1CYP1A2
SCHEMBL24453706 0.78 GPR84 (0.38) SMN1; SMN2GPR84PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4710923-A2 INDOLE AHR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2026-03-18 — — EP disclosed
EP-4396191-B1 COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING JAGUAHR THERAPEUTICS PTE LTD (SG) 2026-02-18 — — EP disclosed
EP-3612030-B1 INDOLE AHR INHIBITORS AND USES THEREOF IKENA ONCOLOGY INC (US) 2025-12-24 — — EP disclosed
US-20250129092-A1 COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING JAGUAHR THERAPEUTICS PTE LTD (SG) 2025-04-24 — — US disclosed
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-12077542-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-09-03 — — US disclosed
CN-110831600-B Indole AHR inhibitors and uses thereof 医肯纳肿瘤学公司 2023-10-17 — — CN disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2020-10-22 — — US disclosed
US-10689388-B1 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2020-06-23 — — US disclosed
US-10689388-B1 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2020-06-23 — — US disclosed
EP-3612030-A2 INDOLE AHR INHIBITORS AND USES THEREOF Kyn Therapeutics (US) 2020-02-26 — — EP disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 — — US disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 — — US disclosed
CN-110831600-A Indole AHR inhibitors and uses thereof 金恩医疗公司 2020-02-21 — — CN disclosed
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2018-11-15 — — US disclosed
WO-2018195397-A2 INDOLE AHR INHIBITORS AND USES THEREOF KYN THERAPEUTICS (US) 2018-10-25 — — WO disclosed
EP-2149552-A1 5,6 substituted benzamide derivatives as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2010-02-03 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 SMN1; SMN2 4883/4885HTR1D 179/4885HTR6 39/4885
US-20250129092-A1 COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING AHR, ARNT, AIPL1 SMN1; SMN2 4692/4885HTR1D 1041/4885HTR6 340/4885
US-10570138-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 SMN1; SMN2 4883/4885HTR1D 179/4885HTR6 39/4885
US-11358969-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 SMN1; SMN2 4883/4885HTR1D 179/4885HTR6 39/4885
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 SMN1; SMN2 4883/4885HTR1D 179/4885HTR6 39/4885
US-10689388-B1 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 SMN1; SMN2 4883/4885HTR1D 179/4885HTR6 39/4885
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 SMN1; SMN2 4883/4885HTR1D 179/4885HTR6 39/4885
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 SMN1; SMN2 4883/4885HTR1D 179/4885HTR6 39/4885
US-12077542-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 SMN1; SMN2 4883/4885HTR1D 179/4885HTR6 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.